Emerging therapies for gout

Rheumatic Disease Clinics of North America

Volumn 40, Issue 2, 2014, Pages 375-387

  Edwards, N Lawrence ^a   So, Alexander ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Febuxostat; Gout; Interleukin 1 inhibitor; Lesinurad; Melanocortin; Pegloticase; Ulodesine; Urate lowering therapy

Indexed keywords

ALLOPURINOL; ARHALOFENATE; CANAKINUMAB; CASPASE INHIBITOR; COLCHICINE; CORTICOTROPIN; CRYOPYRIN; FEBUXOSTAT; INFLAMMASOME; INTERLEUKIN 1BETA; LESINURAD; MELANOCORTIN RECEPTOR; PEGLOTICASE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOFISOPAM; TRIAMCINOLONE ACETATE; ULODESINE; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ACETAMIDE DERIVATIVE; ANTIGOUT AGENT; ANTIRHEUMATIC AGENT; BENZODIAZEPINE DERIVATIVE; HYBRID PROTEIN; IMINOSUGAR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MACROGOL DERIVATIVE; MELANOCORTIN; MONOCLONAL ANTIBODY; PHENYLACETIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOGLYCOLIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE; URATE OXIDASE;

ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; CYTOKINE PRODUCTION; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; GOUT; HUMAN; HYPERURICEMIA; INFECTION; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS;

ACETAMIDES; ADRENOCORTICOTROPIC HORMONE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BENZODIAZEPINES; GOUT; GOUT SUPPRESSANTS; HUMANS; IMINO FURANOSES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MELANOCORTINS; PHENYLACETATES; POLYETHYLENE GLYCOLS; PYRIMIDINONES; RECOMBINANT FUSION PROTEINS; THIAZOLES; THIOGLYCOLATES; TRIAZOLES; URATE OXIDASE; URICOSURIC AGENTS;

EID: 84898600187     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.01.013     Document Type: Review

References (39)

1. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63(10):3136-3141.
2. Janssens H.J., Janssen M., van de Lisdonk E.H., et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet 2008, 371(9627):1854-1860.
3. Terkeltaub R.A., Furst D.E., Bennett K., et al. High vs low dosing of oral colchicine for early acute gout flare: twenty-four hour outcome results of the first randomized, placebo-controlled, dose comparison colchicine trial. Arthritis Rheum 2010, 62(4):1060-1068.
4. Zhang W., Doherty M., Pascual E., et al. EULAR Committee for International Clinical Studies including Therapeutics. EULAR evidence based recommendations for gout. Part II. Management report of a Task Force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
5. Khanna D., Fitzgerald J.D., Khanna P.P., et al. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64(10):1431-1446.
6. Becker M.A., Schumacher H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461.
7. Edwards N.L. Quality of care in patients with gout: why is management suboptimal and what can be done about it?. Curr Rheumatol Rep 2011, 13(2):154-159.
8. Perez-Ruiz F., Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?. Arthritis Rheum 2007, 57:1324-1328.
9. Perez-Ruiz F., Calabozo M., Pijoan J.I., et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res 2002, 47:356-360.
10. Perez-Ruiz F., Sundy J., Krishnan E., et al. Efficacy and safety of Lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, double-blind, placebo-controlled, Phase 2B study. Ann Rheum Dis 2011, 70(Suppl 3):104.
11. Fleishmann R., Shen Z., Yeh L.T., et al. Lesinurad (DEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate-lowering effects in gout patients with 100% response achieved for all combination dose regimens. Ann Rheum Dis 2011, 70(Suppl 3):188.
12. Fitzpatrick D, Drummond W, Pappas J, et al. Effects of a purine nucleoside phosphorylase inhibitor, BCX4208, on serum uric acid concentrations in patients with gout. ACR/ARHP Annual Meeting. 2010. Abst 150.
13. Hollister A.S., Becker M., Terkeltaub R., et al. BCX4208 shows synergistic reductions in serum uric acid in gout patients when combined with allopurinol. Ann Rheum Dis 2011, 70(Suppl 3):183.
14. O'Day R., Williams K.M., Graham G.G. Urate-lowering therapy: uricosurics. Future Medicine 2013, 174-188. 10.2217/ebo.13.104.
15. Gregoire F., Zhang F., Clarke H.J., et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Ensrinol 2009, 23:975-988.
16. Giamarellos-Bourboulis E.J., Mouktarond M., Bodar E., et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1β by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009, 68:273-278.
17. Martinon F., Petrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
18. So A., DeSmedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
19. Joosten L.A., Ea H.K., Netea M.G., et al. Interleukin-1β activation during acute joint inflammation: a limited role for the NLRP3 inflammasome in vivo. Joint Bone Spine 2010, 78(2):107-110.
20. Lachmann H.J., Quartier P., So A., et al. The emerging role of interleukin-1β in autoinflammatory disease. Arthritis Rheum 2011, 63:314-324.
21. Ghosh P., Cho M., Rawat G., et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013, 65:1381-1384.
22. Direz G., Noel N., Guyot C., et al. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure. Joint Bone Spine 2012, 79:631.
23. Tran A.P., Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 2011, 14:e33-e37.
24. Funck-Brentano T., Salliot C., Leboime A., et al. First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine. Rheumatology (Oxford) 2011, 50:622-624.
25. Chen K., Fields T., Mancuso C.A., et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010, 40:210-214.
26. Singh D., Huston K.K. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 2009, 15:366.
27. Gratton S.B., Scalapino K.J., Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 2009, 61:1268-1270.
28. Schlesinger N., Alten R.E., Bardin T., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized, multicenter, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71(11):1839-1848.
29. Terkeltaub R., Sundy J., Schumacher H.R., et al. The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, cross-over pilot study. Ann Rheum Dis 2009, 68:1613-1617.
30. Terkeltaub R.A., Schumacher H.R., Carter J.D., et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013, 15:R25.
31. Mitha E., Schumacher H.R., Fouche L., et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 2013, 52:1285-1292.
32. Schlesinger N., Mysler E., Lin H.Y., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study. Ann Rheum Dis 2011, 70:1264-1271.
33. Getting S.J., Kaneva M., Bhadresa Y., et al. Melanocortin peptide therapy for the treatment of arthritic pathologies. ScientificWorldJournal 2009, 9:1394-1414. 10.1100/sw2009.163.
34. Daoussis D., Antonopoulos I., Yiannopoulos G., et al. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine 2013, 80:291-294.
35. Wannamaker W., Davies R., Namchuk M., et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release if IL-1β and IL-18. J Pharmacol Exp Ther 2007, 321:509-516.
36. Edwards N.L., Sundy J.S., Forsythe A., et al. Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ 2011, 14(1):10-15.
37. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221-226.
38. Schumacher H.R., Evans R.R., Saag K.G., et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis care & Research 2012, 64:1462-1470.
39. So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis and Rheumatism 2010, 62:3064-3076.